Insiders · ICUI

Daniel Woolson

VP, GM-Infusion Capital at Icu Medical Inc/de (ICUI)

Daniel Woolson has filed 18 insider reports with the SEC since February 2021, as VP and GM-Infusion Capital at Icu Medical Inc/de (ICUI). In the last 12 months Daniel Woolson sold $1.7M of stock on the open market. In the latest filing, on August 13, 2026, Daniel Woolson sold 5,417 shares of Icu Medical Inc/de (ICUI) for $982K at an average of $181.33.

Filings
18
Companies
1
Bought on market
None
Sold on market
$3.04M

Companies where Daniel Woolson is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Icu Medical Inc/de logo
ICUI
Icu Medical Inc/de
VP, GM-Infusion Capital17,062$3.04M$176.91Aug 13, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Daniel Woolson with

Other insiders at the same companies

Questions about Daniel Woolson

What is Daniel Woolson's role at Icu Medical Inc/de?
Daniel Woolson reports to the SEC as VP and GM-Infusion Capital at Icu Medical Inc/de (ICUI), according to the latest filing on August 13, 2026.
How many shares does Daniel Woolson own?
After the latest filing that states it, Daniel Woolson directly owned 17,062 shares of Icu Medical Inc/de (ICUI). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Daniel Woolson bought or sold stock recently?
The most recent open-market sale was on August 13, 2026: sold 5,417 shares of Icu Medical Inc/de (ICUI) for $982K at an average of $181.33.
How do I get alerts when Daniel Woolson files?
Follow Daniel Woolson on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Daniel Woolson (SEC CIK 0001698998). Totals count each trade once, skipping amendments whose original is on file, from Feb 19, 2021 on. View on SEC EDGAR